BRAF gene mutation in the natural history of papillary thyroid carcinoma: Diagnostic and prognostic implications;Mutação do gene BRAF na história natural do carcinoma papilar da tireóide: Implicações diagnósticas e prognósticas

Acta Medica Portuguesa

Volumn 24, Issue SUPPL.4, 2011, Pages 855-868

  Lopes, J Pedro ^a   Fonseca, E ^b  

^a University of Porto   (Portugal)

^b UNIVERSITY OF PORTO   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

ADENINE; B RAF KINASE; CELL SURFACE RECEPTOR; GLUTAMIC ACID; MITOGEN ACTIVATED PROTEIN KINASE; THYMINE; VALINE;

AMINO ACID SUBSTITUTION; ANAPLASTIC CARCINOMA; CELL PROLIFERATION; CYTOLOGY; GENE MUTATION; HISTOLOGY; HISTORY; HUMAN; LYMPH NODE METASTASIS; POINT MUTATION; PROGNOSIS; REVIEW; SIGNAL TRANSDUCTION; SURVIVAL; THYROID PAPILLARY CARCINOMA; TUMOR DIFFERENTIATION; TUMOR GROWTH; TUMOR RECURRENCE;

CARCINOMA; HUMANS; MUTATION; PROGNOSIS; PROTO-ONCOGENE PROTEINS B-RAF; THYROID NEOPLASMS;

EID: 84864261028     PISSN: None     EISSN: 16460758     Source Type: Journal    
DOI: None     Document Type: Review

References (138)

1. CIAMPI R, NIKIFOROV YE: RET/PTC rearrangements and BRAF mutations in thyroid tumorigenesis. Endocrinology 2007;148:936-941
2. TANG KT, LEE CH: BRAF mutation in papillary thyroid carcinoma: pathogenic role and clinical implications. J Chin Med Assoc 2010;73:113-128
3. TROVISCO V, SOARES P, PRETO A, CASTRO P, MAXIMO V, SOBRINHO-SIMÕES M: Molecular genetics of papillary thyroid carcinoma: great expectations. Arq Bras Endocrinol Metabol 2007;51:643-653
4. FAGIN JA, MITSIADES N: Molecular pathology of thyroid cancer: diagnostic and clinical implications. Best Pract Res Clin Endocrinol Metab 2008;22:955-969
5. NUCERA C, GOLDFARB M, HODIN R, PARANGI S: Role of B-Raf(V600E) in differentiated thyroid cancer and preclinical validation of compounds against B-Raf(V600E). Biochim Biophys Acta 2009;1795:152-161
6. DAVIES L, WELCH HG: Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA 2006;295:2164-7
7. a ed. Philadelphia: Saunders 2004.
8. MACIEL RM, KIMURA ET, CERUTTI JM: [Pathogenesis of differentiated thyroid cancer (papillary and follicular)]. Arq Bras Endocrinol Metabol 2005;49:691-700
9. SHIBRU D, CHUNG KW, KEBEBEW E: Recent developments in the clinical application of thyroid cancer biomarkers. Curr Opin Oncol 2008;20:13-8
10. HANDKIEWICZ-JUNAK D, CZARNIECKA A, JARZAB B: Molecular prognostic markers in papillary and follicular thyroid cancer: Current status and future directions. Mol Cell Endocrinol 2010, doi:10.1016/j.mce.2010.01.007
11. LEENHARDT L, GROSCLAUDE P, CHERIE-CHALLINE L: Increased incidence of thyroid carcinoma in france: a true epidemic or thyroid nodule management effects? Report from the French Thyroid Cancer Committee. Thyroid 2004;14:1056-60
12. PUXEDDU E, MORETTI S: Clinical prognosis in BRAF-mutated PTC. Arq Bras Endocrinol Metabol 2007;51:736-747
13. LEE JH, LEE ES, KIM YS: Clinicopathologic significance of BRAF V600E mutation in papillary carcinomas of the thyroid: a meta-analysis. Cancer 2007;110:38-46
14. XING MZ: BRAF mutation in papillary thyroid cancer: Pathogenic role, molecular bases, and clinical implications. Endocr Rev 2007;28:742-762
15. PUXEDDU E, DURANTE C, AVENIA N, FILETTI S, RUSSO D: Clinical implications of BRAF mutation in thyroid carcinoma. Trends Endocrinol Metab 2008;19:138-145
16. AL-BRAHIM N, ASA SL: Papillary thyroid carcinoma: an overview. Arch Pathol Lab Med 2006;130:1057-62
17. PARK YJ, KIM YA, LEE YJ, et al.: Papillary microcarcinoma in comparison with larger papillary thyroid carcinoma in BRAF(V600E) mutation, clinicopathological features, and immunohistochemical findings. Headeck 2009
18. ROBINSON MJ, COBB MH: Mitogen-activated protein kinase pathways. Curr Opin Cell Biol 1997;9:180-6
19. FRATTINI M, FERRARIO C, BRESSAN P, et al.: Alternative mutations of BRAF, RET and NTRK1 are associated with similar but distinct gene expression patterns in papillary thyroid cancer. Oncogene 2004;23:7436-440
20. KIMURA ET, NIKIFOROVA MN, ZHU Z, KNAUF JA, NIKIFOROV YE, FAGIN JA: High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res 2003;63:1454-7
21. SOARES P, TROVISCO V, ROCHA AS, et al.: BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC. Oncogene 2003;22:4578-80
22. DAVIES H, BIGNELL GR, COX C, et al.: Mutations of the BRAF gene in human cancer. Nature 2002;417:949-954
23. WAN PT, GARNETT MJ, ROE SM, et al.: Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 2004;116:855-867
24. MERCER KE, PRITCHARD CA: Raf proteins and cancer: B-Raf is identified as a mutational target. Biochim Biophys Acta 2003;1653:25-40
25. TROVISCO V, SOARES P, SOBRINHO-SIMÕES M: B-RAF mutations in the etiopathogenesis, diagnosis, and prognosis of thyroid carcinomas. Hum Pathol 2006;37:781-6
26. GARNETT MJ, MARAIS R: Guilty as charged: B-RAF is a human oncogene. Cancer Cell 2004;6:313-9
27. FAGIN JA: How thyroid tumors start and why it matters: kinase mutants as targets for solid cancer pharmacotherapy. J Endocrinol 2004;183:249-256
28. ESPINOSA AV, PORCHIA L, RINGEL MD: Targeting BRAF in thyroid cancer. Br J Cancer 2007;96:16-20
29. SALEHIAN B, LIU Z: Genetic alterations in differentiated thyroid cancers. Endocr Metab Immune Disord Drug Targets 2009;9:257-268
30. HUBBARD SR: Oncogenic mutations in B-Raf: some losses yield gains. Cell 2004;116:764-6
31. CIAMPI R, KNAUF JA, KERLER R, et al.: Oncogenic AKAP9-BRAF fusion is a novel mechanism of MAPK pathway activation in thyroid cancer. J Clin Invest 2005;115:94-101
32. MORETTI S, MACCHIARULO A, DE FALCO V, et al.: Biochemical and molecular characterization of the novel BRAF(V599Ins) mutation detected in a classic papillary thyroid carcinoma. Oncogene 2006;25:4235-40
33. CIAMPI R, NIKIFOROV YE: Alterations of the BRAF gene in thyroid tumors. Endocr Pathol 2005;16:163-172
34. FUSCO A, VIGLIETTO G, SANTORO M: A new mechanism of BRAF activation in human thyroid papillary carcinomas. J Clin Invest 2005;115:20-3
35. XING M: BRAF mutation in thyroid cancer. Endocr Relat Cancer 2005;12:245-262
36. TROVISCO V, SOARES P, PRETO A et al: Type and prevalence of BRAF mutations are closely associated with papillary thyroid carcinoma histotype and patients' age but not with tumour aggressiveness. Virchows Arch 2005(a);446:589-595
37. CASTRO P, REBOCHO AP, SOARES RJ et al: PAX8-PPARgamma rearrangement is frequently detected in the follicular variant of papillary thyroid carcinoma. J Clin Endocrinol Metab 2006;91:213-220
38. OLER G, EBINA KN, MICHALUART P, JR., KIMURA ET, CERUTTI J: Investigation of BRAF mutation in a series of papillary thyroid carcinoma and matched-lymph node metastasis reveals a new mutation in metastasis. Clin Endocrinol (Oxf) 2005;62:509-511
39. TROVISCO V, SOARES P, SOARES R, MAGALHAES J, SA-COUTO P, SOBRINHO-SIMÕES M: A new BRAF gene mutation detected in a case of a solid variant of papillary thyroid carcinoma. Hum Pathol 2005;36:694-7
40. CARTA C, MORETTI S, PASSERI L et al: Genotyping of an Italian papillary thyroid carcinoma cohort revealed high prevalence of BRAF mutations, absence of RAS mutations and allowed the detection of a new mutation of BRAF oncoprotein (BRAF(V599lns). Clin Endocrinol (Oxf) 2006;64:105-9
41. HOU P, LIU D, XING M: Functional characterization of the T1799-1801del and A1799-1816ins BRAF mutations in papillary thyroid cancer. Cell Cycle 2007;6:377-9
42. TROVISCO V, VIEIRA DE CASTRO I, SOARES P, et al: BRAF mutations are associated with some histological types of papillary thyroid carcinoma. J Pathol 2004;202:247-251
43. GRADÍSSIMO V: Role of the BRAF gene alterations in the natural history of papillary thyroid carcinoma. Porto: Dissertação de Doutoramento apresentada à Faculdade de Medicina do Porto 2008
44. KIM TY, KIM WB, SONG JY et al: The BRAF mutation is not associated with poor prognostic factors in Korean patients with conventional papillary thyroid microcarcinoma. Clin Endocrinol (Oxf) 2005(b);63:588-593
45. SEDLIAROU I, SAENKO V, LANTSOV D et al: The BRAFT1796A transversion is a prevalent mutational event in human thyroid microcarcinoma. Int J Oncol 2004;25:1729-35
46. UGOLINI C, GIANNINI R, LUPI C et al: Presence of BRAF V600E in very early stages of papillary thyroid carcinoma. Thyroid 2007;17:381-8
47. NIKIFOROVA MN, KIMURA ET, GANDHI M et al: BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab 2003;88:5399-404
48. NAMBA H, NAKASHIMA M, HAYASHI T et al: Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers. J Clin Endocrinol Metab 2003;88:4393-7
49. XING M, VASKO V, TALLINI G et al: BRAF T1796A transversion mutation in various thyroid neoplasms. J Clin Endocrinol Metab 2004;89:1365-8
50. KUMAGAI A, NAMBA H, SAENKO VA et al: Low frequency of BRAFT1796A mutations in childhood thyroid carcinomas. J Clin Endocrinol Metab 2004;89:4280-4
51. LIMA J, TROVISCO V, SOARES P et al: BRAF mutations are not a major event in post-Chernobyl childhood thyroid carcinomas. J Clin Endocrinol Metab 2004;89:4267-71
52. NIKIFOROVA MN, CIAMPI R, SALVATORE G et al: Low prevalence of BRAF mutations in radiation-induced thyroid tumors in contrast to sporadic papillary carcinomas. Cancer Lett 2004;209:1-6
53. HUNT J: Understanding the genotype of follicular thyroid tumors. Endocr Pathol 2005;16:311-321
54. SOARES P, FONSECA E, WYNFORD-THOMAS D, SOBRINHO-SIMÕES M: Sporadic ret-rearranged papillary carcinoma of the thyroid: a subset of slow growing, less aggressive thyroid neoplasms? J Pathol 1998;185:71-8
55. TALLINI G, SANTORO M, HELIE M et al: RET/PTC oncogene activation defines a subset of papillary thyroid carcinomas lacking evidence of progression to poorly differentiated or undifferentiated tumor phenotypes. Clin Cancer Res 1998;4:287-294
56. NIKIFOROV YE, ROWLAND JM, BOVE KE, MONFORTE-MUNOZ H, FAGIN JA: Distinct pattern of ret oncogene rearrangements in morphological variants of radiation-induced and sporadic thyroid papillary carcinomas in children. Cancer Res 1997;57:1690-4
57. NIKIFOROV YE: RET/PTC rearrangement in thyroid tumors. Endocr Pathol 2002;13:3-16
58. BASOLO F, GIANNINI R, MONACO C et al: Potent mitogenicity of the RET/PTC3 oncogene correlates with its prevalence in tall-cell variant of papillary thyroid carcinoma. Am J Pathol 2002;160:247-254
59. ADENIRAN AJ, ZHU Z, GANDHI M et al: Correlation between genetic alterations and microscopic features, clinical manifestations, and prognostic characteristics of thyroid papillary carcinomas. Am J Surg Pathol 2006;30:216-222
60. DI CRISTOFARO J, MARCY M, VASKO V, et al.: Molecular genetic study comparing follicular variant versus classic papillary thyroid carcinomas: association of N-ras mutation in codon 61 with follicular variant. Hum Pathol 2006;37:824-830
61. FILETTI S, DURANTE C, TORLONTANO M: Nonsurgical approaches to the management of thyroid nodules. Nat Clin Pract Endocrinol Metab 2006;2:384-394
62. CHUNG KW, YANG SK, LEE GK et al: Detection of BRAFV600E mutation on fine needle aspiration specimens of thyroid nodule refines cyto-pathology diagnosis, especially in BRAF600E mutation-prevalent area. Clin Endocrinol (Oxf) 2006;65:660-6
63. COHEN Y, ROSENBAUM E, CLARK DP et al: Mutational analysis of BRAF in fine needle aspiration biopsies of the thyroid: a potential application for the preoperative assessment of thyroid nodules. Clin Cancer Res 2004;10:2761-5
64. HAYASHIDA N, NAMBA H, KUMAGAI A et al: A rapid and simple detection method for the BRAF(T1796A) mutation in fine-needle aspirated thyroid carcinoma cells. Thyroid 2004;14:910-5
65. PIZZOLANTI G, RUSSO L, RICHIUSA P et al: Fine-needle aspiration molecular analysis for the diagnosis of papillary thyroid carcinoma through BRAF V600E mutation and RET/PTC rearrangement. Thyroid 2007;17:1109-15
66. ROWE LR, BENTZ BG, BENTZ JS: Utility of BRAF V600E mutation detection in cytologically indeterminate thyroid nodules. Cytojournal 2006;3:10
67. SALVATORE G, GIANNINI R, FAVIANA P et al: Analysis of BRAF point mutation and RET/PTC rearrangement refines the fine-needle aspiration diagnosis of papillary thyroid carcinoma. J Clin Endocrinol Metab 2004;89:5175-80
68. SAPIO MR, POSCA D, RAGGIOLI A et al: Detection of RET/PTC, TRK and BRAF mutations in preoperative diagnosis of thyroid nodules with indeterminate cytological findings. Clin Endocrinol (Oxf) 2007;66:678-683
69. XING M, TUFANO RP, TUFARO AP et al: Detection of BRAF mutation on fine needle aspiration biopsy specimens: a new diagnostic tool for papillary thyroid cancer. J Clin Endocrinol Metab 2004(a);89:2867-72
70. JIN L, SEBO TJ, NAKAMURA N et al: BRAF mutation analysis in fine needle aspiration (F-A) cytology of the thyroid. Diagn Mol Pathol 2006;15:136-143
71. NIKIFOROV YE, STEWARD DL, NIKIFOROV MN et al: Role of molecular testing for mutations in improving the fine-needle aspiration (FNA) diagnosis of thyroid nodules (Proceedings of the 77th Annual Meeting of The American Thyroid Association) [abstract]. Thyroid 2006;16:922
72. MAZZAFERRI EL, JHIANG SM: Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 1994;97:418-428
73. DEGROOT LJ, KAPLAN EL, MCCORMICK M, STRAUS FH: Natural history, treatment, and course of papillary thyroid carcinoma. J Clin Endocrinol Metab 1990;71:414-424
74. MAZZAFERRI EL, KLOOS RT: Clinical review 128: Current approaches to primary therapy for papillary and follicular thyroid cancer. J Clin Endocrinol Metab 2001;86:1447-63
75. SHERMAN SI, BRIERLEY JD, SPERLING M et al: Prospective multicenter study of thyroid carcinoma treatment: initial analysis of staging and outcome. National Thyroid Cancer Treatment Cooperative Study Registry Group. Cancer 1998;83:1012-21
76. TANAKA K, SONOO H, HIRONO M et al: Retrospective analysis of predictive factors for recurrence after curatively resected papillary thyroid carcinoma. Surg Today 2005;35:714-9
77. a ed. Lyon: WHO Classification of Tumours 2004
78. MAZZAFERRI EL: Managing small thyroid cancers. JAMA 2006;295:2179-82
79. KEBEBEW E, WENG J, BAUER J et al: The prevalence and prognostic value of BRAF mutation in thyroid cancer. Ann Surg 2007;246:466-70; discussion 70-1
80. KIM KH, SUH KS, KANG DW, KANG DY: Mutations of the BRAF gene in papillary thyroid carcinoma and in Hashimoto's thyroiditis. Pathol Int 2005(a);55:540-5
81. RODOLICO V, CABIBI D, PIZZOLANTI G et al: BRAF V600E mutation and p27 kip1 expression in papillary carcinomas of the thyroid
82. POWELL N, JEREMIAH S, MORISHITA M et al: Frequency of BRAF T1796A mutation in papillary thyroid carcinoma relates to age of patient at diagnosis and not to radiation exposure. J Pathol 2005;205:558-564
83. KIM TY, KIM WB, RHEE YS et al: The BRAF mutation is useful for prediction of clinical recurrence in low-risk patients with conventional papillary thyroid carcinoma. Clin Endocrinol (Oxf) 2006(a);65:364-8
84. XU X, QUIROS RM, GATTUSO P, AIN KB, PRINZ RA: High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines. Cancer Res 2003;63:4561-7
85. XING M, WESTRA WH, TUFANO RP et al: BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J Clin Endocrinol Metab 2005;90:6373-9
86. RIESCO-EIZAGUIRRE G, GUTIERREZ-MARTINEZ P, GARCIA-CABEZAS MA, NISTAL M, SANTISTEBAN P: The oncogene BRAF V600E is associated with a high risk of recurrence and less differentiated papillary thyroid carcinoma due to the impairment of Na+/I-targeting to the membrane. Endocr Relat Cancer 2006;13:257-269
87. LEE JH, LEE ES, KIM YS, WON NH, CHAE YS: BRAF mutation and AKAP9 expression in sporadic papillary thyroid carcinomas. Pathology 2006;38:201-4
88. KIM J, GIULIANO AE, TURNER RR et al: Lymphatic mapping establishes the role of BRAF gene mutation in papillary thyroid carcinoma. Ann Surg 2006(b);244:799-804
89. LUPI C, GIANNINI R, UGOLINI C et al: Association of BRAF V600E mutation with poor clinicopathological outcomes in 500 consecutive cases of papillary thyroid carcinoma. J Clin Endocrinol Metab 2007;92:4085-90
90. WANG Y, JI M, WANG W et al: Association of the T1799A BRAF mutation with tumor extrathyroidal invasion, higher peripheral platelet counts, and over-expression of platelet-derived growth factor-B in papillary thyroid cancer. Endocr Relat Cancer 2008(a);15:183-190
91. FRASCA F, NUCERA C, PELLEGRITI G et al: BRAF(V600E) mutation and the biology of papillary thyroid cancer. Endocr Relat Cancer 2008;15:191-205
92. LEE X, GAO M, JI Y et al: Analysis of differential BRAF(V600E) mutational status in high aggressive papillary thyroid microcarcinoma. Ann Surg Oncol 2009;16:240-5
93. OLER G, CERUTTI JM: High prevalence of BRAF mutation in a Brazilian cohort of patients with sporadic papillary thyroid carcinomas: correlation with more aggressive phenotype and decreased expression of iodide-metabolizing genes. Cancer 2009;115:972-980
94. GUAN H, JI M, BAO R et al: Association of high iodine intake with the T1799A BRAF mutation in papillary thyroid cancer. J Clin Endocrinol Metab 2009;94:1612-7
95. YIP L, NIKIFOROVA MN, CARTY SE et al: Optimizing surgical treatment of papillary thyroid carcinoma associated with BRAF mutation. Surgery 2009;146:1215-23
96. KIM KH, KANG DW, KIM SH, SEONG IO, KANG DY: Mutations of the BRAF gene in papillary thyroid carcinoma in a Korean population. Yonsei Med J 2004;45:818-821
97. SAPIO MR, POSCA D, TRONCONE G et al: Detection of BRAF mutation in thyroid papillary carcinomas by mutant allele-specific PCR amplification (MASA). Eur J Endocrinol 2006;154:341-8
98. BAITEI EY, ZOU M, AL-MOHANNA F et al: Aberrant BRAF splicing as an alternative mechanism for oncogenic B-Raf activation in thyroid carcinoma. J Pathol 2009;217:707-715
99. SYKOROVA V, DVORAKOVA S, RYSKA A et al: BRAFV600E Mutation in the Pathogenesis of a Large Series of Papillary Thyroid Carcinoma in Czech Republic. J Endocrinol Invest 2009
100. JO YS, LI S, SOG JH et al: Influence of the BRAF V600E mutation on expression of vascular endothelial growth factor in papillary thyroid cancer. J Clin Endocrinol Metab 2006;91:3667-70
101. LIU RT, CHEN YJ, CHOU FF et al: No correlation between BRAF V600E mutation and clinicopathological features of papillary thyroid carcinomas in Taiwan. Clin Endocrinol (Oxf) 2005;63:461-6
102. DURANTE C, PUXEDDU E, FERRETTI E et al: BRAF mutations in papillary thyroid carcinomas inhibit genes involved in iodine metabolism. J Clin Endocrinol Metab 2007;92:2840-3
103. COSTA AM, HERRERO A, FRESNO MF et al: BRAF mutation associated with other genetic events identifies a subset of aggressive papillary thyroid carcinoma. Clin Endocrinol (Oxf) 2008;68:618-634
104. BARZON L, MASI G, BOSCHIN IM et al: Characterization of a novel complex BRAF mutation in a follicular variant papillary thyroid carcinoma. Eur J Endocrinol 2008;159:77-80
105. ELISEI R, UGOLINI C, VIOLA D et al: BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study. J Clin Endocrinol Metab 2008;93:3943-9
106. ITO Y, YOSHIDA H, MARUO R et al: BRAF mutation in papillary thyroid carcinoma in a Japanese population: its lack of correlation with high-risk clinicopathological features and disease-free survival of patients. Endocr J 2009;56:89-97
107. FUKUSHIMA T, SUZUKI S, MASHIKO M et al: BRAF mutations in papillary carcinomas of the thyroid. Oncogene 2003;22:6455-7
108. PUXEDDU E, MORETTI S, ELISEI R et al: BRAF(V599E) mutation is the leading genetic event in adult sporadic papillary thyroid carcinomas. J Clin Endocrinol Metab 2004;89:2414-20
109. FUGAZZOLA L, MANNAVOLA D, CIRELLO V et al: BRAF mutations in an Italian cohort of thyroid cancers. Clin Endocrinol (Oxf) 2004;61:239-243
110. PERREN A, SCHMID S, LOCHER T et al: BRAF and endocrine tumors: mutations are frequent in papillary thyroid carcinomas, rare in endocrine tumors of the gastrointestinal tract and not detected in other endocrine tumors. Endocr Relat Cancer 2004;11:855-860
111. DOMINGUES R, MENDONCA E, SOBRINHO L, BUGALHO MJ: Searching for RET/PTC rearrangements and BRAF V599E mutation in thyroid aspirates might contribute to establish a preoperative diagnosis of papillary thyroid carcinoma. Cytopathology 2005;16:27-31
112. PORRA V, FERRARO-PEYRET C, DURAND C et al: Silencing of the tumor suppressor gene SLC5A8 is associated with BRAF mutations in classical papillary thyroid carcinomas. J Clin Endocrinol Metab 2005;90:3028-35
113. ROSENBAUM E, HOSLER G, ZAHURAK M, COHEN Y, SIDRANSKY D, WESTRA WH: Mutational activation of BRAF is not a major event in sporadic childhood papillary thyroid carcinoma. Mod Pathol 2005;18:898-902
114. VASKO V, HU S, WU G et al: High prevalence and possible de novo formation of BRAF mutation in metastasized papillary thyroid cancer in lymph nodes. J Clin Endocrinol Metab 2005;90:5265-9
115. GIORDAO TJ, KUICK R, THOMAS DG et al: Molecular classification of papillary thyroid carcinoma: distinct BRAF, RAS, and RET/PTC mutation-specific gene expression profiles discovered by DA microarray analysis. Oncogene 2005;24:6646-56
116. DI CRISTOFARO J, SILVY M, LANTEAUME A, MARCY M, CARAYON P, DE MICCO C: Expression of tpo mRNA in thyroid tumors: quantitative PCR analysis and correlation with alterations of ret, Braf, ras and pax8 genes. Endocr Relat Cancer 2006(a);13:485-495
117. MATSUKUMA S, YOSHIHARA M, KASAI F et al: Rapid and simple detection of hot spot point mutations of epidermal growth factor receptor, BRAF, and NRAS in cancers using the loop-hybrid mobility shift assay. J Mol Diagn 2006;8:504-512
118. SARGENT R, LIVOLSI V, MURPHY J, MANTHA G, HUNT JL: BRAF mutation is unusual in chronic lymphocytic thyroiditis-associated papillary thyroid carcinomas and absent in non-neoplastic nuclear atypia of thyroiditis. Endocr Pathol 2006;17:235-241
119. PARK SY, PARK YJ, LEE YJ et al: Analysis of differential BRAF(V600E) mutational status in multifocal papillary thyroid carcinoma: evidence of independent clonal origin in distinct tumor foci. Cancer 2006;107:1831-8
120. ZUO H, NAKAMURA Y, YASUOKA H et al: Lack of association between BRAF V600E mutation and mitogen-activated protein kinase activation in papillary thyroid carcinoma. Pathol Int 2007;57:12-20
121. ABROSIMOV A, SAENKO V, ROGOUNOVITCH T et al: Different structural components of conventional papillary thyroid carcinoma display mostly identical BRAF status. Int J Cancer 2007;120:196-200
122. TAKAHASHI K, EGUCHI H, ARIHIRO K et al: The presence of BRAF point mutation in adult papillary thyroid carcinomas from atomic bomb survivors correlates with radiation dose. Mol Carcinog 2007;46:242-8
123. ERICKSON LA, JIN L, NAKAMURA N, BRIDGES AG, MARKOVIC SN, LLOYD RV: Clinicopathologic features and BRAF(V600E) mutation analysis in cutaneous metastases from well-differentiated thyroid carcinomas. Cancer 2007;109:1965-71
124. BRZEZIANSKA E, PASTUSZAK-LEWANDOSKA D, WOJCIECHOWSKA K et al: Investigation of V600E BRAF mutation in papillary thyroid carcinoma in the Polish population. Neuro Endocrinol Lett 2007;28:351-9
125. GIANNINI R, UGOLINI C, LUPI C et al: The heterogeneous distribution of BRAF mutation supports the independent clonal origin of distinct tumor foci in multifocal papillary thyroid carcinoma. J Clin Endocrinol Metab 2007;92:3511-6
126. HAY R, MACRAE E, BARBER D, KHALIL M, DEMETRICK DJ: BRAF mutations in melanocytic lesions and papillary thyroid carcinoma samples identified using melting curve analysis of polymerase chain reaction products. Arch Pathol Lab Med 2007;131:1361-7
127. NAKAYAMA H, YOSHIDA A, NAKAMURA Y et al: Clinical significance of BRAF (V600E) mutation and Ki-67 labeling index in papillary thyroid carcinomas. Anticancer Res 2007;27:3645-9
128. RODRIGUES R, ROQUE L, ESPADINHA C et al: Comparative genomic hybridization, BRAF, RAS, RET, and oligo-array analysis in aneuploid papillary thyroid carcinomas. Oncol Rep 2007;18:917-926
129. GOUTAS N, VLACHODIMITROPOULOS D, BOUKA M, LAZARIS AC, NASIOULAS G, GAZOULI M: BRAF and K-RAS mutation in a Greek papillary and medullary thyroid carcinoma cohort. Anticancer Res 2008;28:305-8
130. WANG YL, WANG JC, WU Y et al: Incidentally simultaneous occurrence of RET/PTC, H4-PTEN and BRAF mutation in papillary thyroid carcinoma. Cancer Lett 2008(b);263:44-52
131. TROVISCO V, COUTO JP, CAMESELLE-TEIJEIRO J et al: Acquisition of BRAF gene mutations is not a requirement for nodal metastasis of papillary thyroid carcinoma. Clin Endocrinol (Oxf) 2008;69:683-5
132. JO YS, HUANG S, KIM YJ et al: Diagnostic value of pyrosequencing for the BRAF V600E mutation in ultrasound-guided fine-needle aspiration biopsy samples of thyroid incidentalomas. Clin Endocrinol (Oxf) 2009;70:139-144
133. HENDERSON YC, SHELLENBERGER TD, WILLIAMS MD et al: High rate of BRAF and RET/PTC dual mutations associated with recurrent papillary thyroid carcinoma. Clin Cancer Res 2009;15:485-491
134. KIM SK, SONG KH, LIM SD et al: Clinical and pathological features and the BRAF(V600E) mutation in patients with papillary thyroid carcinoma with and without concurrent Hashimoto thyroiditis. Thyroid 2009;19:137-141
135. SANTARPIA L, SHERMAN SI, MARABOTTI A, CLAYMAN GL, EL-NAGGAR AK: Detection and molecular characterization of a novel BRAF activated domain mutation in follicular variant of papillary thyroid carcinoma. Hum Pathol 2009;40:827-833
136. CHUANG TC, CHUANG AY, POETA L, KOCH WM, CALIFANO JA, TUFANO RP: Detectable BRAF mutation in serum DNA samples from patients with papillary thyroid carcinomas. Head Neck 2009
137. ZATELLI MC, TRASFORINI G, LEONI S et al: BRAF V600E mutation analysis increases diagnostic accuracy for papillary thyroid carcinoma in fine-needle aspiration biopsies. Eur J Endocrinol 2009;161:467-473
138. PELLEGRITI G, DE VATHAIRE F, SCOLLO C et al: Papillary thyroid cancer incidence in the volcanic area of Sicily. J Natl Cancer Inst 2009;101:1575-83